Download - Bayer HealthCare

Bayer HealthCare
A Company Overview | 2013

Published by:
Bayer HealthCare AG,
Corporate Communications & Public Affairs
Oliver Renner, 51368 Leverkusen, Germany
English version:
Language Service, Currenta GmbH & Co. OHG, Germany
Edited by:
Christina Sehnert, christina.sehnert@bayer.com
Bärbel Doormann, baerbel.doormann@bayer.com
6
8
10
12
Contents
innovations in health care 3
Animal Health 6
Consumer Care 8
Medical Care 10
Pharmaceuticals 12
research and development 16
Product Supply 20
Business development 22
Social commitment 24
Contacts 26
Appendix
Key fi gures 2012
Headquarter sites / headcounts
Bayer HealthCare
Executive Committee
Cover:
Aspirin – even after
more than 110 years,
this successful product
is still undergoing further
development.
Forward-looking Statements
This brochure may contain forward-looking statements based on current assumptions
and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, fi nancial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer’s public reports which are available on the Bayer website
at www.bayer.com. The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or developments.
Product names are mostly registered trademarks. All trademarks are printed in
italics. not all products are marketed by Bayer in all countries.

innovations in
health care
Bayer HealthCare is among the world’s foremost innovators in the
fi eld of pharmaceutical and medical products. The subgroup’s
mission is to research, develop, manufacture and market innovative
products that improve the health of people and animals throughout
the world.
3

4
“For me it was terrific that we developed three new cancer
drugs within such a short period of time.” Dr. Dimitris
Voliotis isn’t just saying this because he is in charge
of clinical development activities in Oncology at Bayer
HealthCare. He also has a very personal relationship
to this disease. “My father died of cancer when I was
25.” As a scientist, he always keeps in mind that it is
ultimately fathers, mothers, sons and daughters who
suffer from – and often die of – cancer.
Voliotis is one of more than 55,300 employees at
Bayer HealthCare, and one of the approximately
7,500 employees who work in research and de-
velopment. Each of
“ Science For A Better
Life – medical progress
for the benefit
of patients”
our employees, like
Dimitris Voliotis, is
driven by his or her
own personal moti-
vation. Their fundamental
objective is
always to alleviate people’s suffering, improve their
well-being and extend their lives.
For 150 years, Bayer has been developing products
that help to improve people’s quality of life. Bayer
HealthCare – one of three Bayer subgroups – researches,
develops and produces products that
improve the health of people and animals worldwide,
concentrating on innovations in areas where
there is a high medical need.
We are currently in the process of extending our
range with five new products in quick succession:
an anticoagulant, two cancer drugs, an eye medicine
and a drug to treat pulmonary hypertension.
And further innovations are in the pipeline – fully in
line with our mission “Bayer: Science For A Better
Life.”
Many groundbreaking medicines have been created
by Bayer over the past more than 100 years. Many
of them are known around the world. For example,
Aspirin has been on the market since 1899, yet
scientists are still continually discovering new
aspects of this once-in-a-century pharmaceutical.
Bayer’s research into completely new principles of
action has proven successful: not just in oncology,
but also in the treatment of cardiovascular and
infectious diseases as well. We offer therapeutic
options for people with multiple sclerosis who are
hoping to halt the progression of this disease of the
central nervous system.
We also have a broad range of contraceptives for
women who want safe and convenient birth control,
as well as products to alleviate menopause symptoms.
In addition, we have solutions for people with
diabetes who need to monitor their blood glucose.
Our range of products also includes devices for
diagnostic imaging and medical therapy.
And we have products for people who want to
choose their own medicines to prevent or treat
everyday ailments, as well as dietary supplements
to support a healthy diet.
The health of animals is equally important to us,
whether that of companion animals on the one hand

or farm animals for food production on the other.
So no matter whether a dog is tormented by
fleas or ticks, pigs have come down with a
bacterial infection of the intestines, or a cat is
suffering from infestation with worms – we
can offer products to treat each of these
cases.
In order to concentrate optimally on the re-
spective target areas and markets, we have
divided our business into four divisions –
Pharmaceuticals, Consumer Care, Medical
Care and Animal Health. Our strategy is
geared toward achieving above-average,
profitable and sustainable growth.
Our work is concentrated on innovation. Our
research pipeline contains projects that have great
potential, above all to produce innovative products
capable of providing better treatment of the chronic
diseases that are increasingly prevalent in the
world’s aging population.
In growth markets such as Brazil, China and
Russia, we are working to further extend our port-
folio. Furthermore, we want to further strengthen
our business in the market for non-prescription
medicines.
As a global company with sites around the world
and a differentiated portfolio, we are committed to a
workforce characterized by diversity. The ingenuity
of our employees is a cornerstone of our success.
Bayer HealthCare therefore endeavors to attract the
most talented employees from around the world.
The analgesic Aspirin was launched in 1899 and
was one of the first successful drug products in the
history of Bayer. Research into the medicine (left)
continues to this day – for example, studies into
new formulations of the active ingredient of Aspirin.
Protecting, curing and caring for animals –
Bayer Animal Health has been developing and
producing medicinal and care products for farm
and companion animals in line with this philosophy
for years (center).
Many diseases today remain difficult or impossible
to treat. Scientists at Bayer HealthCare (right)
are therefore looking for new active ingredients to
treat diseases with a high level of medical need.
Diversity is particularly valuable in the health care
industry, and developing innovative products in
this research-oriented field requires cooperation
between numerous partners. The more diversified
this team, the greater the creative potential released
by the cooperation. In this way, the multifaceted
knowledge, experience and values can be used to
design innovative customer solutions and address
global challenges.
We hope this brochure will give you an insight into
the diverse world and strengths of Bayer Health-
Care. We wish you pleasant reading.
Seeing is the
most important
sense for
humans: 80 percent
of what we
perceive comes
via the eyes. But
when the visual
cells in the center
of the retina die off
as a result of old
age, the window
on the world
closes. An eye
medicine has been
co­developed with
the U.S. company
Regeneron for the
treatment of wet
age­related macular
degeneration.
5

Sick pets can also impair the health of humans, for example by
transmitting disease pathogens.
6
Animal Health
net sales 2012: approx. € 1.3 billion
Headquarters: Monheim, Germany

The goals of the Animal Health Division are to maintain the health of animals and
cure veterinary diseases, with the focus primarily on treating infectious diseases
and repelling parasites. in livestock – animals that play a role in food production – the
safety of drug and care products is paramount for food safety. Companion animals receive
special attention in clinical practice: in view of the emotional ties that people have
to them but also their close relationship to the family, it is vital that they receive dependable,
easy-to-use and safe medication in order to safeguard both their well-being and
that of their owners.
With more than 100 different animal health and care products worldwide for livestock and
companion animals, the division is one of the most successful suppliers in the field of
veterinary medicine. Animal Health is well positioned in the steadily growing market for
antiparasitic products for companion animals. The Advantage family of flea control
products for dogs and cats was again one of Bayer HealthCare’s best-selling products
in 2012, generating annual sales of roughly € 495 million.
The innovative flea and tick collar Seresto for dogs and cats joined the portfolio of
parasiticides for companion animals in 2012. The collar’s patented polymer matrix
ensures controlled low-dose release of the tried and true active ingredients flumethrin
and imidacloprid into the animal’s coat. Seresto provides effective protection for up to
eight months from a single application, and is available on the market in Europe, the
United States and new Zealand.
The acquisition of the animal health business of Teva Pharmaceuticals in the United
States has strengthened both the companion animals and farm animals businesses
and means that Bayer is now represented in all major therapeutic areas. The companion
animal products acquired comprise mainly a complete range of dermatological
products but also a wide spectrum of dietary supplements to support joint and
gastrointestinal functions and other whole body health care products, while the farm
animal products acquired from Teva cover a wide range of anti-infectives, parasiticides,
anti-inflammatories and reproduction hormones.
Bayer has signed a distribution agreement with the Irish veterinary manufacturer
norbrook in Germany and France with the objective of supplementing the existing
portfolio so that customers can be offered comprehensive solutions.
AniMAl HEAlTH DIVISIOn
7

More and more people are taking
responsibility for their own health.
For this reason, self­medication
is becoming increasingly
important.
8
Consumer Care
net sales 2012: approx. € 3.9 billion
Headquarters: Morristown, new Jersey, uSA

A growing number of individuals worldwide select medicines themselves for the
prevention or treatment of common ailments, as well as nutritional supplements to
support a healthy diet. Many of them place their trust in tried-and-true non-prescription
or over-the-counter (oTC) products from Bayer HealthCare’s Consumer Care Division.
one example is Aspirin, a more than 110-year-old brand that enjoys an unsurpassed
level of global familiarity.
Consumer Care currently ranks among the top consumer health care companies in the world.
The division operates in more than 100 countries and maintains 14 manufacturing
sites and two product research and development centers.
With more than 170 brands around the world and nine global brands generating
annual sales of more than € 100 million each, the Consumer Care Division is
well positioned to take advantage of the sustained growth forecast for the OTC
market.
The division holds a balanced portfolio of strong brands in all major categories,
including analgesics, cardiovascular risk prevention, cough and cold, dermatology,
gastrointestinals and nutritionals.
In fact, some of the world’s best-known and most trusted over-the-counter medications
and nutritional supplements including Aspirin, Aleve, Alka­Seltzer, Bepanthen/
Bepanthol, Berocca, Canesten, Elevit, Redoxon, Rennie, Supradyn, Talcid and
One A Day are part of the Consumer Care portfolio.
The division has a strong track record of growth in emerging markets and continues
to invest in fast-growing regions around the world to increase its global footprint and
advance its international portfolio of products.
In addition to focusing its growth in emerging markets, Consumer Care continues to
seek Merger & Acquisition (M&A) opportunities to deepen its pipeline and diversity of
product offerings.
ConSuMEr CArE DIVISIOn
9

egular blood glucose monitoring helps
people with diabetes keep their blood sugar levels
normal.
10
Medical Care
net sales 2012: approx. € 2.7 billion
Headquarters: Tarrytown, new york, uSA

Bayer HealthCare’s Medical Care Division is comprised of two business units – radiology
& interventional and Diabetes Care. The radiology & interventional unit was formed in 2012
through the combination of Bayer HealthCare’s contrast agent and medical devices
businesses.
radiology & interventional is a global leader in developing and manufacturing contrast
agents used in X-ray, computed tomography (CT) and magnetic resonance imaging
(MRI), as well as injection systems for diagnostic and therapeutic medical proce-
dures in CT, MRI and cardiovascular and peripheral vascular disease. The unit also
provides service support for the systems as well as medical data management
products.
Products include the contrast agents Ultravist, Magnevist and Gadovist/Gadavist;
the injection systems Stellant D and Spectris Solaris EP; the thrombectomy system
AngioJet Ultra; the atherectomy system JetStream; and the Certegra Informatics
Platform.
The products are provided to cardiologists, radiologists and vascular surgeons in
hospitals and out-patient clinical sites through a global direct sales organization,
supplemented in some locations by local distributors.
The Diabetes Care unit is one of the leading providers of blood glucose monitoring
systems, monitors to test glycated hemoglobin (HbA1c), lancing devices and diabetes
management software.
The portfolio of blood glucose meters includes Contour, Contour XT, Contour Next EZ,
Contour Link* and Contour Next Link* (*International alliance with Medtronic, Inc. to
develop innovative next generation diabetes management solutions for patients
worldwide), Contour USB, Contour Next USB, Contour TS and Breeze 2.
Monitors for measurement of glycated hemoglobin include the A1CNow+ monitor for
health care providers and A1CNow Selfcheck for home use.
Outside Europe, these products are generally sold to consumers through pharmacies,
drugstores, mass merchants, hospitals or wholesalers. In Europe, they are sold mainly
through pharmacies.
MEDiCAl CArE DIVISIOn
11

More and more doctors and patients rely on innovative
drugs from Bayer HealthCare’s Pharmaceuticals Division.
12
Pharmaceuticals
net sales 2012: approx. € 10.8 billion
Headquarters: Berlin, Germany

Bayer HealthCare’s success story in the pharmaceuticals business began 125 years
ago. The first product marketed by the “Pharmaceutical Department” of Bayer was
the antipyretic Phenacetin in 1888. Bayer also quickly developed a reputation espe-
cially in the treatment of infectious diseases. Bayer researcher Gerhard Domagk, who
discovered the antibacterial effect of sulfonamides, was awarded the nobel Prize in
Medicine in 1939.
Bayer HealthCare Pharmaceuticals today holds a worldwide leading position in its main
therapeutic areas. The focus on specialty pharmaceuticals and the opportunities
for growth in the field of general medicine offer an outstanding basis for sustainable
expansion. The division combines its strengths in two business units: General
Medicine and Specialty Medicine.
The General Medicine Business Unit develops and markets products that are prescribed
by both general practitioners and medical specialists. Our extensive range
of products in this segment – for the control of high blood pressure, prevention of
myocardial infarction and stroke, and for diabetes management – offer doctors and
patients options in both the treatment and prevention of acute disease conditions.
The company also markets effective drug products to treat bacterial infections, such
as respiratory tract and urinary tract infections. In the field of Men’s Health, the division
offers a wide range of therapeutic options, including treatments for erectile dysfunction
and testosterone deficiency. In 2008, Bayer HealthCare launched a novel oral Factor
Xa inhibitor for the prevention of life-threatening blood clots that is taken once daily in
most indications. This product is now registered in more than 120 countries for the
prevention of thrombosis after elective hip or knee replacement surgery; further
indications have since also been added.
In the field of Women’s Healthcare, the company is currently concentrating on three
areas: contraception, menopause management and the development of gyneco-
logical treatments. Bayer is the world leader in the field of female hormonal contra-
ception, in particular in the area of oral contraception. The “pill” has been helping
women plan their families for more than 50 years.
Bayer HealthCare offers a wide range of different contraceptives to meet individual
needs, including a low-dosage contraceptive which is the first product from a new
class of oral contraceptives whose estrogen component has the same action as
estradiol, an estrogen that is produced by the female body. For women who do not
wish to take a daily contraceptive pill, the company offers long-term intrauterine
contraceptive systems with a duration of action of up to five years. The range also
includes products to relieve the symptoms associated with menopause. In the gynecological
therapy segment, Bayer HealthCare is working to develop new therapeutic
options for conditions with a high level of unmet medical need such as uterine fibroids
(myomas) and endometriosis, a condition in which endometrial cells grow outside
PHArMACEuTiCAlS DIVISIOn
13

14
in 2008, Bayer HealthCare launched a novel oral
Factor Xa inhibitor for the prevention of life­threatening
blood clots. Bayer scientist Dr. Susanne
Röhrig (above) has been conducting research into
the active ingredient for several years.
Bayer researchers Professor Johannes­Peter
Stasch (right), Dr. Stephan Vettel (center) and
Dr. Dieter Neuser in the laboratory in Wuppertal
(photo left) with a model of a lung.
The active ingredient aflibercept is another promising
new product in ophthalmology (below). It is
now available in the world’s main markets for the
treatment of wet age­related macular degeneration.

Continued from page 13
of the uterus. In Europe, Bayer HealthCare has
launched a drug product for the treatment of endometriosis
which is also approved in some countries
in Latin America and Asia/Pacific.
The Specialty Medicine Business Unit offers innovative
therapeutic options to markedly improve the
quality of life for people suffering from severe, chronic
and life-threatening diseases. Some 2.5 million
people worldwide suffer from multiple sclerosis (MS),
a chronic inflammatory disease of the central nervous
system usually occurring in episodes. Bayer Health-
Care was one of the first companies to offer a causal
treatment for this automimmune disease that reduces
the frequency of attacks and in this way can slow
progression of the disease considerably.
Hemophilia A is a rare genetic blood coagulation
disorder that can be effectively treated with blood
coagulation Factor VIII. The Pharmaceuticals Division
is one of the world’s leading manufacturers of drug
products to treat this hereditary disease.
Crucial improvements have been achieved in tar-
geted cancer treatments – therapies that inhibit cell
division and simultaneously disrupt the blood supply
to the tumor. Nexavar, an oral drug containing the
active ingredient sorafenib, is approved for the
treatment of renal cell carcinoma and hepatocellular
carcinoma in many countries. It is also undergoing
studies to investigate its suitability in other forms of
cancer such as breast and thyroid cancer or as an
adjuvant therapy in renal cell carcinoma and hepatocellular
carcinoma.
Another promising cancer drug is regorafenib, which
was granted regulatory approval in the United States
for treatment of metastatic colorectal cancer in Sep-
tember 2012 and for the treatment of gastrointestinal
stromal tumors (GIST) in February 2013. Here, too,
further therapeutic options are being investigated.
Radium-223 dichloride is an investigational alpha
particle-emitting pharmaceutical in development for
the treatment of castrate-resistant prostate cancer
with bone metastases. It was filed for regulatory
approval in the United States and Europe in
December 2012.
Another promising drug that was recently launched
is Eylea, a solution for intravitreal injection containing
the active ingredient aflibercept and used for the
treatment of wet age-related macular degeneration,
which is now available in this indication on the
world’s main markets. Another important indication
for which the drug has been filed for regulatory
approval in Europe is occlusion of the central retinal
vein, which can lead to blood clots and edema in the
retina. Other studies are being conducted to investigate
the use of aflibercept in various diseases of the
ocular fundus.
The Pharmaceutical Division’s products are primarily
distributed through wholesalers, pharmacies and
hospitals. In addition, products are also co-developed
and co-marketed in partnerships with other
companies.
PHArMACEuTiCAlS DIVISIOn
15

Every tumor is unique. Biology lab assistant
Kirsten Steiner­Hahn fi rst inspects tissue specimens
with the naked eye. The tumor samples then
undergo numerous further analyses.
16
research and
development

€1,962 million of the Bayer Group’s total research and development (r&D) spending
went to Bayer HealthCare in 2012, corresponding to 65.1 percent of the group’s entire
research expenditure, or 10.5 percent of Bayer HealthCare’s sales. Some 7,500 employees
research and develop innovative active ingredients for the treatment of diseases
where there is a high level of medical need.
Drug discovery in Bayer HealthCare’s Pharmaceuticals Division is concentrated on the areas of
Cardiology, Oncology, Hematology and Women’s Healthcare, while the corresponding
mechanisms of inflammation and the development of new therapeutic options in oph-
thalmology are also of interest. The division aims to identify low-molecular-weight sub-
stances as well as to develop new biologics. It also evolves products that have already
been granted regulatory approval, for example by developing novel formulations. In
many of these projects, Bayer’s scientists work together in close collaboration with
external cooperation partners.
rESEArCH AnD DEvEloPMEnT
One example of an innovative active ingredient is the anticoagulant Xarelto (rivaroxaban)
which was invented in Bayer’s laboratories in Wuppertal and co-developed with
Janssen Pharmaceuticals. The extensive clinical trial program conducted for rivaroxaban
which will have involved more than 100,000 patients once all studies are completed
makes it the most studied oral, direct Factor Xa inhibitor in the world today. The
clinical development program investigated the inhibitor’s potential in the prevention and
treatment of a broad spectrum of acute and chronic thromboembolic disorders,
including stroke prevention in patients with atrial fibrillation, treatment of deep vein
thrombosis and pulmonary embolism, prevention of recurrent deep vein thrombosis or
pulmonary embolism, and finally secondary prevention of acute coronary syndrome.
Another innovative substance from Bayer’s research laboratories is riociguat, the first
drug from a new class of vasodilatative substances. This oral product is being developed
for the treatment of various forms of pulmonary hypertension, a rare but lifethreatening
disease. Further priorities in cardiology research are heart failure and kidney
disorders. The functions of the heart and kidneys are mutually interdependent and
heart and kidney diseases often share common underlying disease mechanisms.
Despite major progress in the fight against cancer, there is still a high medical need for
therapies to prolong life and improve the quality of life. The development pipeline in
Oncology comprises various targeted antibodies, antibody-drug conjugates as well as
low-molecular-weight substances. These include, in addition to Nexavar (sorafenib), a
co-development with Onyx Pharmaceuticals, the substance regorafenib, which inhibits
various enzymes involved in tumor growth and the formation of new blood vessels
(neoangiogenesis), and radium-223 dichloride, a novel alpha-pharmaceutical drug
which is being co-developed with the norwegian company Algeta ASA for the treatment
of tumor types which have already formed metastases in the bones. Radium-223
dichloride emits targeted alpha radiation to eliminate cancer cells in the bones. It was
filed for regulatory approval for the treatment of castration-resistant prostate
17

Team analysis: Tanja Wesarg and Marco Jaspers use a mass
spectrometer to analyze protein structures.
on average, the
development of
a pharmaceutical
product to market
maturity takes about
10 to 12 years
and costs roughly
half a billion euros.
Generally only one
out of every 5,000
to 10,000 examined
substances ultimately
receives marketing
authorization.
18
cancer patients with bone metastases in Europe and
the United States in 2012. Together with its partner
OncoMed Pharmaceuticals, Bayer HealthCare is
working in the innovative research area of cancer
stem cell research. Cancer stem cells are believed to
play a signifi cant role in the development, metastasis
and recurrence of cancer. The objective is to jointly
develop new therapeutic options to target cancer
stem cells.
Eylea (afl ibercept), a drug product that is being developed
in collaboration with Regeneron Pharmaceuticals
Inc., could make an important contribution in the treatment
of eye diseases. The product, which is injected
into the vitreous body of the eye, is registered in various
countries and regions for the treatment of wet agerelated
macular degeneration and in the United States
also for the treatment of macular edema due to central
retinal vein occlusion. Further clinical trials on the treatment
of additional diseases of the ocular fundus are
currently ongoing.
Development of a pharmaceutical product: The long road
research
up to 10,000
substances
In vitro efficacy
tests
250
substances
oscillating, disposable bioreactor: Dr. Uwe Langer from Biotechnology
Development at Bayer HealthCare, developer Jörg Kauling and Annette Waldhelm
from Bayer Technology Services (left to right) check the product quality.
4.7
substances
0 2 4 6 8 10
In the fi eld of women’s health care, Bayer HealthCare
conducts research to discover innovative approaches to
treat gynecological disorders such as endometriosis and
uterine fi broids. The company has launched Visanne
(dienogest), a new treatment option for endometriosis, in
Europe. Bayer HealthCare is also working on further developing
the broad spectrum of contraceptives, ranging
from the development of new, low-dose oral contraceptives
with a fl exible extended dosing regimen through to
a new, low-dose intrauterine system. This long-term
contraceptive with a duration of action of up to three
years was granted regulatory approval in the European
Union (trade name: Jaydess) in December 2012 and in
the United States (trade name: Skyla) in early 2013.
The Medical Care Division conducts R&D into nextgeneration
advances in diabetes monitoring, radiology/
interventional radiology and cardiology to improve the
current portfolio of marketed products. The division
conducts proprietary R&D and also forms strategic
alliances with other companies to share technology and
Preclinical Clinical studies Application
Phase i Phase ii Phase iii
submitted
Efficacy and safety tests,
animal testing with
the final 10 to 20
substances
Tolerability
testing in
healthy human
subjects
3.3
substances
Testing in a
small
number of
patients
1.5
substances
Testing
generally in
several thousand
patients
1.2
substances
Documentation
examined by
regulatory
authorities
Approved
1
substance
12 years

expertise. The current R&D focus in blood glucose
monitoring includes ease-of-use, meter accuracy,
and software to simplify data capture and analysis. In
radiology and interventional, the division is focused on
investments in informatics, contrast media, fluid delivery
systems, interventional therapeutic catheters and other
accessories to deliver innovative integrated solutions to
customers. R&D activities focus on contrast agents for
high field MRI and low radiation CT; solutions to improve
diagnostic outcome and radiology workflow efficiency;
equipment service; and vascular intervention systems for
treating constricted or blocked blood vessels. The
division’s expanded global network of leading clinical
researchers supports R&D activities through innovative
clinical studies.
Research and development in the Animal Health Division
is concentrated on the identification and registration of
new active ingredients for applications in companion
and farm animals. Another priority is the development of
innovative formulations and new applications for existing
research and Development Projects (Phase iii)*
Aflibercept Treatment of diabetic macular edema
active ingredients. The close collaboration with the re-
search departments of Bayer HealthCare Pharma and
Bayer CropScience offers a unique competitive advantage
thanks to the opportunities to share data and
research results. In all of Bayer Animal Health’s developments,
the focus is always on user friendliness and
safety for both humans and animals. The division’s main
development sites are located in Monheim (Germany),
Shawnee (USA) and Auckland (new Zealand).
In the Analgesics category, Bayer Aspirin has been
a leader in pain relief for over 110 years. The new Bayer
Advanced Aspirin represents the most exciting Aspirin
innovation to date in the United States. Launched by the
Consumer Care Division in 2011, the product was the
result of more than five years of research and development
and uses breakthrough patented technology to
reduce the Aspirin particles into micro-particles. This
next generation of Aspirin targets younger, more active
consumers.
Aflibercept Prevention of abnormal retinal angiogenesis following
pathological myopia
BAY 86-6150 (rFVIIa mutein) Treatment of hemophilia A (Phase II/III)
BAY 94-9027 (rFVIII mutein) Treatment of hemophilia A
Ciprofloxacin Inhale Treatment of pulmonary infections
LCS-16 (ULD LnG Contraceptive System) Intrauterine contraception, duration of use: up to 5 years
Prasterone ** Treatment of vulvovaginal atrophy
Rivaroxaban Prevention of major adverse cardiac events (MACE)
Sodium deoxycholate *** Injection for reduction of submental fat
Sorafenib Treatment of breast cancer
Sorafenib Treatment of liver cancer, adjuvant therapy
Sorafenib Treatment of kidney cancer, adjuvant therapy
Sorafenib Treatment of thyroid cancer
Tedizolid Treatment of complicated skin and lung infections
rESEArCH AnD DEvEloPMEnT
* as of February 11, 2013
** prasterone = vaginorm
*** sodium deoxycholate =
ATX-101
The nature of drug discovery and
development is such that not all
compounds can be expected to
meet the predefined project
goals. It is possible that any or all
of the projects listed above may
have to be discontinued due to
scientific and / or commercial
reasons and will not result in
commercialized products. It is also
possible that the requisite Food
and Drug Administration (FDA),
European Medicines Agency
(EMA) or other regulatory
approvals will not be granted for
these compounds.
19

High-quality active ingredients are
fi lled at the Supply Center in
Bergkamen.
20
Product Supply

Bayer HealthCare manufactures products at almost 60 sites around the world which
are managed by Product Supply. The production of active ingredients for prescription
medicines is conducted primarily at the production sites in Wuppertal and Bergkamen
(Germany) and Berkeley and Emeryville (united States). They are processed and packaged
as finished pharmaceuticals in plants around the world.
A broad spectrum of different pharmaceutical presentations is covered: solid formulations such
as tablets, sugar-coated tablets and powders, semi-solid ointments and creams, and
liquid drug products for application, for example, as injections or infusions. Hormonal
contraceptives are produced as sugar- or film-coated tablets but also, for example, as
intrauterine systems. These formulation and packaging activities are based in Berlin,
Leverkusen and Weimar (Germany), Garbagnate (Italy), Turku (Finland), São Paulo
(Brazil), Beijing (China), as well as various other sites in Europe, Asia and Latin America.
Kogenate, a drug product for the treatment of hemophilia, is manufactured in Berkeley
(United States) using a biotechnology process, while Betaferon/Betaseron for the
treatment of multiple sclerosis is produced in Emeryville (United States).
The main production sites for non-prescription (over-the-counter) drug products are
located in Bitterfeld-Wolfen and Grenzach-Wyhlen (Germany), Cimanggis (Indonesia),
Lerma (Mexico), Myerstown (United States) and Madrid (Spain). The globally marketed
animal health products are mainly manufactured at the sites in Kiel (Germany) and
Shawnee (United States).
In addition to drug products for humans and animals, medical devices for diagnosis
and therapy are produced in the United States. Bayer HealthCare supplies a total of
more than 20,000 articles. The reason for this large number is the different presentations
of individual products and packaging – for example, different formulations,
dosages, pack sizes and language versions.
Bayer HealthCare Product Supply steers the subgroup’s entire supply chain, from raw
material sourcing through manufacturing to distribution, utilizing a global production
network consisting of its own sites and those of contract manufacturers. In this way
the company aims for continuous improvement of costs, flexibility and delivery reliability,
maintaining high standards of quality, health, safety and environmental protection on
a global basis.
The manufacture of pharmaceutical products is subject to extraordinarily stringent
quality standards. These standards are known collectively as “Good Manufacturing
Practice” (GMP). Compliance with these requirements is regularly audited by internal
experts, regulatory authorities and external consultants.
ProDuCT SuPPly
21

Fostering real partnerships which offer both sides the opportunity
to develop and grow – that is the partnering philosophy of Bayer
HealthCare.
Business development

As an innovation- and growth-oriented company, Bayer HealthCare also invests in
setting up and maintaining collaborations with external partners. These partnerships
cover a broad variety of models ranging from r&D collaborations, licensing and co-
marketing agreements to regional alliances and acquisitions.
Strategic alliances with international partners from academia are an important pillar of the
company’s R&D strategy. Examples are the joint research center for innovative therapeutic
approaches at Tsinghua University (China) and the collaboration with the
German Cancer Research Center (Heidelberg). Other collaborations at earlier stage
include the multi-target drug discovery alliance with Evotec AG from Germany in the
area of endometriosis.
With the targeted anticancer drug Nexavar (sorafenib), the Pharmaceuticals Division
and Onyx Pharmaceuticals, Inc., USA, have gone all the way from drug discovery to
market. Another example in the area of Oncology is the successful co-development of
radium-223 dichloride with Algeta ASA from norway. Bayer HealthCare just recently
submitted this substance for marketing authorization in the EU and the United States
for the treatment of castration-resistant prostate cancer patients with bone metastases.
In collaboration with Regeneron Pharmaceuticals, Inc., Eylea (aflibercept) has
been successfully launched for the treatment of wet age-related macular degenera-
tion and central retinal vein occlusion. Another example of a fruitful partnership is the
co-development and co-promotion agreement with Janssen Pharmaceuticals for the
anticoagulant Xarelto (rivaroxaban). This collaboration has led to launches in multiple
locations worldwide.
Bayer HealthCare Animal Health recently acquired the U.S. animal health business of
Teva Pharmaceutical Industries. This transaction reinforces Bayer’s product offering in
the USA with anti-infectives for livestock and adds reproductive hormones to the
existing portfolio. The acquisition also strengthens the company’s companion animal
franchise with the addition of dermatological, pet wellness and nutraceutical products.
The Consumer Care Division continues to focus its business development efforts to
strengthen its position in the United States and to accelerate growth in emerging
markets including Brazil, China and Russia. In addition, the division will expand its
portfolio into adjacent business categories, as well as Rx to OTC switch opportunities.
BuSinESS DEvEloPMEnT
23

in developing countries in particular, Bayer HealthCare
is committed to giving people access to conscious family
planning.
24
Social commitment

in the 21st century, the world will be strongly shaped by the effects of population growth
in developing countries and emerging markets and by demographic change in numerous
industrialized countries. Developing countries in particular are home to increasing numbers
of people who lack access to the necessary pharmaceutical products and medical
care. Bayer HealthCare is committed to the principles of sustainable development and
accepts responsibility in society. At the center of all our employees’ actions are human
and animal health and environmental protection.
in the context of the company’s “access to medicine” strategy, Bayer HealthCare provides
medicines free of charge to combat the neglected tropical diseases that affect
around 1 billion people worldwide. For example, in 2012 Bayer HealthCare doubled
the number of Lampit tablets that it will donate for the treatment of Chagas disease,
a widespread disease in Latin America, to one million tablets per year over the next five
years. Bayer also collaborates with the WHO in programs to combat African sleeping
sickness, malaria and multiresistant tuberculosis. The company is participating in the
Global Alliance for TB Drug Development to develop a new therapy that will shorten
the treatment period for tuberculosis from at present at least six months to four
months.
As the market leader in the field of hormonal contraceptives, Bayer HealthCare has
been supporting family planning programs in a global network of governmental and
non-governmental organizations (nGOs) worldwide for more than 50 years.
The company has initiated new partnerships to ensure long-term access to hormonal
contraceptives for women in developing countries. In late 2012, for example, Bayer
HealthCare and the Bill & Melinda Gates Foundation signed an agreement guaranteeing
access to safe and reversible contraception for at least 27 million women in
developing countries over a six-year period.
Medical Care supports patient and other non-governmental organizations, including
the International Diabetes Federation (IDF), the Foundation of European nurses in
Diabetes (FEnD) and the Juvenile Diabetes Research Foundation (JDRF).
Consumer Care supports a range of social initiatives focused on education and
research, health and social needs as well as cultural initiatives.
SoCiAl CoMMiTMEnT
25

ConTACTS AT BAYER HEALTHCARE CoRPoRATE CoMMUnICATIonS & PUBLIC AFFAIRS
BAYER HEALTHCARE
Oliver Renner
oliver.renner@bayer.com
DIVISIONS
Animal Health
Jessica Federer
jessica.federer@bayer.com
Consumer Care
Tricia McKernan
tricia.mckernan@bayer.com
Medical Care
Dr. Gisela Lenz
gisela.lenz@bayer.com
Pharmaceuticals
Oliver Renner
oliver.renner@bayer.com
REGIONS
Europe/Canada
Alexander Siedler
alexander.siedler@bayer.com
Asia/Pacific
Su Ngoh Lee
sungoh.lee@bayer.com
China
Yan Lin
yan.lin@bayer.com
Japan
Miho Oka
miho.oka@bayer.com
Latin America/Africa/Middle East
Diana Panqueva
diana.panqueva@bayer.com
North America
Rosemarie Yancosek
rosemarie.yancosek@bayer.com
Status: April 2013

Bayer HealthCare
names – Figures – Facts | 2013

Key fi gures 2012
Bayer HealthCare 2011 2012 Change
€ million % Fx(& p) adj. %
Sales 17,169 18,612 8.4 4.2
EBITDA 4,502 3,815 -15.3
Special items ­200 ­1,253
EBIT 3,191 2,154 -32.5
Special items ­176 ­1,582
Gross cash fl ow 3,254 2,614 -19.7
net cash fl ow 3,357 3,543 5.5
Sales by division 2011 2012 Change
€ million % Fx(& p) adj. %
Animal Health 1,186 1,303 9.9 4.2
Consumer Care 3,534 3,853 9.0 5.6
Medical Care 2,500 2,653 6.1 2.2
Pharmaceuticals 9,949 10,803 8.6 4.2
Sales by region 2011 2012 Change
€ million % Fx adj. %
Europe 6,376 6,484 1.7 0.9
north America 4,360 4,961 13.8 5.5
Asia/Pacifi c 3,656 4,203 15.0 6.2
Latin America/Africa/Middle East 2,777 2,964 6.7 5.6
Best-Selling Pharmaceuticals Products 2011 2012 Change
€ million % Fx adj. %
Betaferon/Betaseron 1,117 1,216 8.9 4.2
Kogenate 1,075 1,182 10.0 5.2
YAZ/Yasmin/Yasminelle 1,070 1,045 -2.3 -5.0
Nexavar 725 792 9.2 4.2
Mirena 581 677 16.5 9.4
Adalat 640 670 4.7 -2.3
Avalox/Avelox 486 486 0.0 -5.0
Aspirin Cardio 404 476 17.8 12.3
Glucobay 362 408 12.7 3.6
Xarelto 86 322 274.4 265.9
Levitra 332 307 -7.5 -9.1
Cipro/Ciprobay 232 229 -1.3 -5.1
Zetia 179 207 15.6 7.5
Diane 182 194 6.6 4.9
Fosrenol 147 187 27.2 18.0
Total 7,618 8,398 10.2 5.2
Proportion of Pharmaceuticals sales 77 % 78 %
Best-Selling Consumer Health Products 2011 2012 Change
€ million % Fx adj. %
Contour (Medical Care) 640 722 12.8 8.5
Advantage product line (Animal Health) 420 495 17.9 10.6
Aspirin* (Consumer Care) 471 494 4.9 1.3
Ultravist (Medical Care) 316 324 2.5 -1.5
Aleve/naproxen (Consumer Care) 285 323 13.3 5.4
Bepanthen/Bepanthol (Consumer Care) 235 269 14.5 13.9
Canesten (Consumer Care) 224 250 11.6 7.8
Gadovist/Gadavist (Medical Care) 160 209 30.6 27.2
One A Day (Consumer Care) 174 196 12.6 4.0
Iopamiron (Medical Care) 185 174 -5.9 -12.3
Total 3,110 3,456 11.1 6.2
Proportion of Consumer Health sales 43 % 44 % Fx (& p) adj. = currency- (and portfolio-)adjusted | Fx adj. = currency-adjusted
* Sales of Aspirin (including Aspirin Complex) – including Aspirin Cardio, which is refl ected in sales of the
Pharmaceuticals segment – increased by 10.9% (Fx adj. +6.4%) in 2012 to €970 million (2011: €875 million).

Germany
United States
China
Japan
Mexico
Brazil
Italy
Russian Fed.
France
Spain
Turkey
Argentina
Indonesia
India
Canada
Finland
Colombia
United Kingdom
Switzerland
Venezuela
Pakistan
Republic Korea
United Arab. Emir.
El Salvador
Australia
Poland
Guatemala
Philippines
Netherlands
Headquarter sites of Bayer HealthCare and its divisions
Tarrytown (Medical Care)
Morristown (Consumer Care)
Headcount according to country
1,210
1,140
1,100
1,068
2,077
1,927
1,637
765
741
693
671
668
644
629
615
553
525
507
478
456
417
377
269
260
256
2,620
Monheim (Animal Health)
Leverkusen (Bayer HealthCare)
7,103
7,755
Berlin (Pharmaceuticals)
Employees by segment
Total number of employees: 55,300
Consumer
Health
17,600
Pharmaceuticals
37,700
13,301

Bayer HealthCare Executive Committee
Bayer HealthCare is managed by its Executive Committee. This body is com-
posed of the four divisional heads, the heads of Research and Development as
well as the heads of the cross-divisional platform functions Central Administration
& Organization, Corporate Communications & Public Affairs, Global Business
Development & Licensing, Human Resources, Law and Patents and Product
Supply. The Executive Committee sets the course for the company’s future.
Its task is to make strategic decisions that lead to a sustained increase in the
company’s value.
Prof. Andreas Busch
Head of Global Drug
Discovery
Andreas Günther
Head of Human
Resources
Erica L. Mann
Head of the Consumer
Care Division
Dr. Dirk Ehle
Head of the Animal
Health Division
Dr. Hartmut Klusik
Head of Product
Supply
Oliver Renner
Head of Corporate
Communications &
Public Affairs
Andreas Fibig
Head of the Pharmaceuticals
Division
Alan Main
Head of the Medical
Care Division
Nigel Sheail
Head of Global
Business Development
& Licensing
Prof. Wolfgang Plischke
Member of the Board of
Management of Bayer AG
and interim Chairman of
Bayer HealthCare
Dr. Stefan Gehring
Head of Law and
Patents and Compliance
Officer
Dr. Kemal Malik
Head of Development
and Chief Medical
Officer of the Pharmaceuticals
Division
Manfred Vehreschild
CFO and Head of
Central Administration
& Organization
Status: April 2013